CHEK1 and ovarian carcinoma: While CHK2 polymorphisms have been extensively studied in thyroid cancer, there is a lack of reports on CHK1 polymorphisms, which have been studied in nasopharyngeal cancer (NPC) and ovarian cancer [123,124].